8 results about "Plasma serum" patented technology

Soluble gp120 (sgp120) is associated to HIV-1-induced immune dysfunction, such as chronic immune activation. However, the detection of sgp120 in biological fluids such as plasma, serum, cervicovaginal fluids, and cerebrospinal fluids is challenging. The present application relates to novel methods and kits for the detection of sgp120 in biological fluids. These methods and kits are based on the use of specific combinations of sgp120-binding molecules recognizing particular domains of sgp120, notably the N-terminal 8-stranded β-sandwich structure, the constant region 1 and 2 (C1-C2) portion, the bridging sheet of the Co-Receptor Binding Site (CoRBS), and / or the CD4-binding domain.

The application provides a full-passive microfluidic whole blood sample preparation device, which comprises, from bottom to top, a bottom support layer, a bottom hydrophilic layer, a bottom adhesive layer, a middle main body layer, a liquid outlet channel layer, an upper surface hydrophilic layer of the liquid outlet channel, a first intermediate adhesive layer, an upper layer main body layer, a second intermediate adhesive layer, a top cover layer and a product collection and storage cavity sealing patch which are laminated and assembled in sequence. The application does not need any external driving force or active surface treatment, and only relies on the material properties and ingenious structure design, so that the plasma / serum can be automatically and efficiently separated from trace whole blood, and the application has the advantages of simple structure, low cost, convenient operation, one-time use, instant detection application and the like.

The present invention relates to a cell-free transcriptional electrochemical biosensor and to the use of the same for detecting specific molecular analytes, such as specific antibodies, proteins, small molecules, nucleic acids, and derivatives thereof, in complex arrays of biological samples, such as plasma, serum, blood, saliva, sweat, and the like, wherein said biosensor is based on the activation of the transcription of a specific RNA strand, induced by recognition with the analyte. The invention further relates to a method for the detection of specific molecular analytes in complex arrays of biological samples, said method being based on the use of said cell-free transcriptional electrochemical biosensor.

The application belongs to the technical field of biology, and particularly relates to a novel biomarker for screening and diagnosis of beta-thalassemia and application thereof. The application provides a novel polypeptide cluster biomarker for screening and diagnosis of beta-thalassemia based on polypeptides in plasma / serum obtained in vitro from patients, which has the advantages of high sensitivity and high specificity. The biomarker provided by the application can be detected by mass spectrometry, and the detection method is stable and efficient, and does not need to adopt cumbersome steps for inspection, thereby providing laboratory support for screening and diagnosis and treatment of beta-thalassemia.

The invention discloses a method for efficiently and rapidly extracting nucleic acid based on a paramagnetic particle method, and belongs to the technical field of molecular biological detection. A lysis solution used in the method is prepared from the following components: 1 to 4 M of guanidine isothiocyanate, 0.5 to 1.5 percent of Triton X-100, 0.2 to 1 percent of Tween 20, 10 to 50 mM of EDTA (Ethylene Diamine Tetraacetic Acid), 10 to 50 mM of DTT (Diethylene Terephthalate), 4 to 8 percent of PEG (Polyethylene Glycol) 8000 and 1 to 3 M of NaCl. According to the method, ethanol with gradient concentration is used for washing. According to the method disclosed by the invention, the optimized lysis solution is combined with gradient concentration ethanol for washing, so that rapid lysis of cells and efficient extraction of nucleic acid can be realized within 10 minutes; according to the method, volatile organic reagents such as chloroform and Trizol do not need to be used, so that the personal safety of operators is guaranteed; the method is simple in process operation, low in professional requirement on experimental operators and suitable for various complex samples such as plasma and serum, the technical application range is expanded due to wide compatibility, and diversified research requirements are met.

The present invention relates to methods of detecting, characterizing, measuring, and quantifying human and humanized antibodies, and conjugates thereof, that may be present in pre-clinical animal biological samples, or human biological samples, including plasma / serum and tissue samples.

Methods are disclosed to detect, characterize, measure, and quantify human and humanized antibodies, and their conjugates, that may be present in pre-clinical animal biological samples, or human biological samples, including plasma / serum and tissue samples.

The application discloses a diagnosis marker for early chronic obstructive pulmonary disease (COPD) and application thereof, and relates to the technical field of biomedicine. The application is based on the fact that the immunoglobulin glycosylation modification index in plasma / serum can be used as a marker when being combined with the lung function detection index FEV1 / FVC, so as to distinguish the high-risk population of early COPD from the healthy population. The method has the advantages of high prediction accuracy, low cost, high throughput and easy operation.